Sutro Biopharma Announces Pricing of $75 Million Underwritten Offering
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/4/2026
- Wall Street ends lower as solid jobs data fuels hawkish Fed bets
- US nonfarm payrolls blow past expectations in August; unemployment rate steady at 4.1%
- BofA's Hartnett says stay long commodities and gold as 'policy panic' works
- Oil ends week higher on renewed US-Iran strikes, diesel hits record
- TikTok owner ByteDance said to secure $29.6bn loan for AI push
- After-Hours Movers: LULU, IOT, PATH, DOCU, ASAN, GWRE, ZS, PL, SWBI, OXM
- After-Hours Movers: AVGO, SNOW, HPE, NTAP, NTSK, CHPT, FIVE, TLYS, PVH, RARE
- After-Hours Movers: DELL, PANW, GTLB, CRDO, MDB, HPE, SMCI
- After-Hours Movers: WDAY, ADSK, S, RBRK, MRVL, ULTA, GAP, AFRM
- After-Hours Movers: NVDA, CRM, SNPS, CRWD, OKTA, NTNX
Sutro Biopharma (STRO) PT Lowered to $11 at Piper Sandler
April 3, 2024 6:48 AM EDTPiper Sandler analyst Edward Tenthoff lowered the price target on Sutro Biopharma (NASDAQ: STRO) to $11.00 (from $12.00) while maintaining a Overweight rating.
The analyst comments "Sutro partnered preclinical ROR1 ADC STRO-003 with Ipsen for $50 million upfront, $25 million equity investment, >$800 million in milestones plus low-double... More
Sutro Biopharma (STRO) PT Lowered to $18 at Truist Securities
April 2, 2024 4:12 PM EDTTruist Securities analyst Asthika Goonewardene lowered the price target on Sutro Biopharma (NASDAQ: STRO) to $18.00 (from $25.00) while maintaining a Buy rating.
The analyst comments "In the next 12 months, we see 3 potential events that could be an inflection point to shares and/or... More
